Responses
New approaches to the management of ILD
S8 Rituximab Therapy For Refractory Myositis Related Interstitial Lung Disease Unresponsive To Conventional Immunosuppression: The Bristol Interstitial Lung Disease Service Experience
Compose a Response to This Article
Other responses
No responses have been published for this article.